Alto Neuroscience’s (ANRO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Alto Neuroscience’s Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($2.69) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($3.26) EPS, FY2027 earnings at ($3.23) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($1.77) EPS.

Separately, Wedbush reiterated a “neutral” rating and issued a $4.00 target price on shares of Alto Neuroscience in a report on Thursday, May 15th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Alto Neuroscience Price Performance

Shares of ANRO opened at $3.4390 on Monday. The company has a market cap of $93.13 million, a P/E ratio of -1.44 and a beta of 1.84. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $15.04. The company has a quick ratio of 18.43, a current ratio of 18.43 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average price is $2.75 and its 200 day moving average price is $2.73.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). On average, research analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Armistice Capital LLC raised its position in shares of Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock worth $3,456,000 after acquiring an additional 950,000 shares in the last quarter. Marshall Wace LLP acquired a new position in Alto Neuroscience in the fourth quarter valued at approximately $3,542,000. Point72 Asset Management L.P. increased its stake in Alto Neuroscience by 73.1% in the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock valued at $7,158,000 after purchasing an additional 714,461 shares during the last quarter. Woodline Partners LP raised its holdings in Alto Neuroscience by 397.6% during the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company’s stock worth $2,631,000 after purchasing an additional 496,976 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company’s stock worth $2,484,000 after buying an additional 390,190 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.